Serologic response to revaccination with two rubella vaccines
A. D. Brandling-Bennett, R. S. Jackson, S. B. Halstead, C. C. Campbell, K. L. Herrmann, J. F. Modlin, J. D. Meyers and J. J. Witte
Three years after receiving rubella vaccine, 1,060 elementary school
children living on the island of Maui, Hawaii, were revaccinated with
either HPV-77 DE-5 or RA 27/3 rubella vaccine given subcutaneously or
intranasally in order to compare the effectiveness of these two vaccines in
raising antibody titers. RA 27/3 was the more effective booster vaccine,
producing fourfold or greater titer rises in 20.1% of recipients, including
80% of children with hemagglutination-inhibiting antibody titers less than
or equal to 1:40 at the time of revaccination, intranasal revaccination was
not significantly more effective than subcutaneous revaccination, although
it did elicit higher titers in children who responded. Responses differed
according to the vaccine that children had received three years earlier.
Because antibody titers have persisted in vaccinated children, routine
administration of a second dose of rubella vaccine is not currently
recommended.
